Antibiotics: Stalemate over developing new antibiotics shuts off pipeline - chicagotribune.com
Drug companies are abandoning the antibacterial business, citing high development costs, low return on investment and, increasingly, a nearly decade-long stalemate with the Food and Drug Administration over how to bring new antibiotics to market.
Got that? No improved antibiotics because they're not profitable enough. Go bugs.
No comments:
Post a Comment